Ravi Patel, MD
Gastroenterology · South Bend, INNPI 1750607354
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 316 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by AbbVie at 35.8% of the total.
Across 316 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$494
- Gilead$384
- Johnson & Johnson$313
- Boston Scientific$293
- Takeda Pharmaceuticals U.S.A., Inc.$251
- plus $2K from 22 others
Across 87 payments — averaging $2033.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$98K
- Boehringer Ingelheim$69K
- Boehringer Ingelheim RCV GmbH & Co KG$9K
What the payments were for
- Food & beverage$5,604100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 142 | $2,008 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 31 | $494 |
| Gilead | 22 | $384 |
| Johnson & Johnson | 23 | $313 |
| Boston Scientific | 5 | $293 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $251 |
| Pfizer | 7 | $219 |
| Mauna Kea Technologies, Inc. | 6 | $162 |
| Sanofi | 7 | $147 |
| Bristol Myers Squibb | 9 | $139 |
| Nestle Healthcare Nutrition Inc. | 12 | $135 |
| Echosens North America, Inc. | 1 | $121 |
| Bard Peripheral Vascular, Inc. | 1 | $116 |
| Covidien LP | 1 | $97 |
| Braintree Laboratories, Inc. | 6 | $93 |
| Amgen | 4 | $92 |
| Regeneron Healthcare Solutions, Inc. | 4 | $89 |
| Organon | 4 | $87 |
| Madrigal Pharmaceuticals | 3 | $79 |
| Ironwood Pharmaceuticals, Inc | 5 | $67 |
| Ferring Pharmaceuticals Inc. | 3 | $58 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $49 |
| Medtronic | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Intercept Pharmaceuticals, Inc. | 1 | $18 |
| Shionogi Inc | 1 | $18 |
| AMAG Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EXALT Model D$134
- FibroScan$121
- XELJANZ$118
- VELSIPITY$118
- Lutonix Drug Coated Balloon$116
- SPYGLASS$113
How this compares
$5,604 in reported general payments places this provider in the 70th percentile of 323 gastroenterology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 19 | $516,654 |
| RinvoqUpadacitinib | 12 | $106,812 |
| Dupixent PenDupilumab | 14 | $104,782 |
| Cimzia (2 Pack)Certolizumab Pegol | 13 | $74,964 |
| XifaxanRifaximin | 18 | $64,228 |
| CreonLipase/Protease/Amylase | 19 | $46,101 |
| LinzessLinaclotide | 18 | $20,979 |
| Mesalamine | 52 | $17,718 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 236 | $14,747 |
| Esomeprazole Magnesium | 94 | $4,100 |
| Lubiprostone | 23 | $3,180 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 18 | $2,945 |
| Colestipol Hcl | 32 | $2,705 |
| Omeprazole | 225 | $2,213 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 98 | $1,381 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $313 | $516,65419 claims |
| AbbVieRinvoq, Creon, Linzess | $2,008 | $173,89249 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $494 | $64,22818 claims |
| Braintree Laboratories, Inc.Sutab | $93 | $2,94518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 323 gastroenterology providers in Indiana.
Other gastroenterology in South Bend
- John MathisSouth Bend$16K
- Pankaj PatelSouth Bend$11K
- Douglas RexIndianapolis$557K
- Ajay JainIndianapolis$432K
- Jonathan ObertNew Albany$302K
- Monika FischerIndianapolis$258K
- Naga ChalasaniIndianapolis$255K
- Matthew BohmWestfield$239K
- Thomas ImperialeIndianapolis$188K
- Mark GromskiIndianapolis$154K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.